Coronavirus Update - 24th June 2020

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We remain open for business as usual.

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Our work and case studies

Challenge: Rapid development of a scalable route towards an analogue of a new drug substance, with definition of an optimal salt form for formulation

Customer:

US Biotech client developing combined Small Molecule / Biologic immunotherapy treatments

Outcome:

ARCINOVA developed two process route options and selected one on the basis of scalability and process economy. The API free base was generated and a rapid salt screening protocol undertaken. A solubility study was undertaken which showed optimal solubilisation at a set pH. The client was delighted and has filed provisional IP. The drug substance analogue shows superior solubility to the prime API.

 

API Development Case Study BEL